XyloCor Therapeutics is a biopharmaceutical company focused on the development of novel gene therapy for unmet needs in advanced coronary artery disease. In the United States, coronary artery disease is a leading cause of death and disability. Our lead product candidate, XC001, is in clinical development for patients with refractory angina for which there are no treatment options. XyloCor also has a secondary product, XC002, in discovery stage, for patients with cardiac tissue damage from heart attacks.
Company HQ State:
Company HQ Country:
Main Therapeutic Focus:
Lead Product in Development:
XC001 for refractory angina
Development Phase of Primary Product:
Number Of Unlicensed Products (For Which You Are Seeking Partners):